This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF/ICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin.
Women included in the study will be 18-45 years old
undergoing IVF treatments due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility.
All women will be at their first to the third cycle of treatment
women will undergo a fresh ET.
repeated implantation failure (more than 3 cycles of good quality ET without implantation)
moderate-severe endometriosis
hydrosalpinx
fibroid uterus
Heli Alexandroni
Lead sponsor
Shaare Zedek Medical Center
Sponsor institution